Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
Top Cited Papers
Open Access
- 1 January 2016
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 101 (1), 334-342
- https://doi.org/10.1210/jc.2015-3462
Abstract
Context: Hypophosphatasia (HPP) is an inborn error of metabolism that, in its most severe perinatal and infantile forms, results in 50–100% mortality, typically from respiratory complications. Objectives: Our objective was to better understand the effect of treatment with asfotase alfa, a first-in-class enzyme replacement therapy, on mortality in neonates and infants with severe HPP. Design/Setting: Data from patients with the perinatal and infantile forms of HPP in two ongoing, multicenter, multinational, open-label, phase 2 interventional studies of asfotase alfa treatment were compared with data from similar patients from a retrospective natural history study. Patients: Thirty-seven treated patients (median treatment duration, 2.7 years) and 48 historical controls of similar chronological age and HPP characteristics. Interventions: Treated patients received asfotase alfa as sc injections either 1 mg/kg six times per week or 2 mg/kg thrice weekly. Main Outcome Measures: Survival, skeletal health quantified radiographically on treatment, and ventilatory status were the main outcome measures for this study. Results: Asfotase alfa was associated with improved survival in treated patients vs historical controls: 95% vs 42% at age 1 year and 84% vs 27% at age 5 years, respectively (P < .0001, Kaplan-Meier log-rank test). Whereas 5% (1/20) of the historical controls who required ventilatory assistance survived, 76% (16/21) of the ventilated and treated patients survived, among whom 75% (12/16) were weaned from ventilatory support. This better respiratory outcome accompanied radiographic improvements in skeletal mineralization and health. Conclusions: Asfotase alfa mineralizes the HPP skeleton, including the ribs, and improves respiratory function and survival in life-threatening perinatal and infantile HPP.Keywords
This publication has 34 references indexed in Scilit:
- Enzyme-Replacement Therapy in Life-Threatening HypophosphatasiaThe New England Journal of Medicine, 2012
- Hypophosphatasia: Nonlethal disease despite skeletal presentation in utero (17 new cases and literature review)Journal of Bone and Mineral Research, 2011
- Clinical utility gene card for: hypophosphatasiaEuropean Journal of Human Genetics, 2010
- Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasiaEuropean Journal of Pediatrics, 2005
- A Homoallelic Gly317 → Asp Mutation in ALPL Causes the Perinatal (Lethal) Form of Hypophosphatasia in Canadian MennonitesGenomics, 1993
- Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: A multicenter controlled clinical trialPediatric Pulmonology, 1992
- Myopathy with hypophosphatasia.Archives of Disease in Childhood, 1990
- High-Frequency Oscillatory Ventilation Compared with Conventional Mechanical Ventilation in the Treatment of Respiratory Failure in Preterm InfantsThe New England Journal of Medicine, 1989
- Pulmonary Oxygen ToxicityThe New England Journal of Medicine, 1983
- Normobaric Oxygen Toxicity of the LungThe New England Journal of Medicine, 1980